Dr. Lal PathLabs (LALPATHLAB) Q2 25/26 earnings summary

Executive summary

• Revenue and profit grew robustly in Q2 and H1 FY26, driven by increased sample and patient volumes, network expansion in core and underpenetrated markets, and disciplined operational execution.

• Investments in high-end diagnostics, digital assets, AI, and operational efficiency are enhancing capabilities and supporting scalable growth.

• Board approved a 70% interim dividend (INR 7/share) and a 1:1 bonus issue.

• Increased authorized share capital to INR 2,000 million and introduced RSU 2025 employee stock plan.

• Expansion continues in Tier 3/4 towns and core markets with a cluster-based approach.

Financial highlights

• Q2 FY26 consolidated revenue: INR 7,306 million (up from INR 6,602 million YoY); H1 FY26 revenue: INR 1,400 crore (up 11% YoY).

• Q2 EBITDA: INR 224 crore (up 10.8% YoY), margin 30.7%; H1 EBITDA: INR 416 crore, margin 29.7%.

• Q2 PAT: INR 1,522 million (up from INR 1,308 million YoY), margin 20.8%; H1 PAT: INR 286 crore (up 20% YoY).

• EPS for Q2: INR 18.1 (vs INR 15.5 YoY); H1 EPS: INR 33.9 (vs INR 28.3 YoY).

• Net cash as of Sep 30, 2025: INR 1,367 crore; consolidated cash and equivalents: INR 1,161 million.

Outlook and guidance

• Revenue growth guidance for FY26 maintained at 11-12%.

• Margins expected in the 27-28% range for the year, with lower-than-anticipated compression due to efficiency programs and favorable mix.

• No price hikes planned for FY26; GST benefits to be passed to customers.

• Bonus shares to be issued within two months of board approval, subject to shareholder and regulatory approvals.

• Long-term revenue CAGR target of 13-14% seen as realistic with organic growth, periodic price increases, and potential M&A.